Idiopathic intracranial hypertension: the sight-threatening pressure syndrome

A woman in her late twenties, overweight, with a daily frontal headache that is worst first thing in the morning and made worse by lying flat — and who has been told for eighteen months that she has chronic migraine — is a patient in whom idiopathic intracranial hypertension (IIH) must be actively excluded. The consequences of missing it are severe and irreversible.

IIH is raised cerebrospinal fluid pressure without an identifiable cause, predominantly affecting women of reproductive age with a raised BMI. It is not rare — in obese women aged 20–44, the incidence is estimated at 13–20 per 100,000 per year, rising in parallel with obesity rates. The hallmark finding is papilloedema, and the major risk is permanent vision loss.

A. Core clinical — the AU general practice framework

Who gets IIH

IIH affects women in approximately 90% of cases, with a female-to-male ratio of 9:1 in adults. Mean age of onset is 25–35 years; mean BMI at diagnosis is 35–40. Australian case volumes are rising in parallel with BMI trends, with the Royal Victorian Eye and Ear Hospital reporting increasing referrals for IIH workup.

Pre-pubertal children present differently: sex distribution is nearly equal and the BMI dependence is less pronounced. The opening pressure threshold for diagnosis in children is >28 cm H₂O.

Risk factors beyond BMI include: polycystic ovary syndrome (PCOS), obstructive sleep apnoea (bidirectional association; treat both), anaemia, certain drugs (tetracyclines — especially minocycline and doxycycline; retinoids — isotretinoin, acitretin; corticosteroid withdrawal; oral contraceptives; growth hormone; lithium; levothyroxine over-replacement), and recent rapid weight gain.

These drug-related causes produce secondary intracranial hypertension — not IIH — and the treatment is to stop the offending agent. Checking the medication list at every visit is essential.

Symptoms that should trigger suspicion

The clinical picture of IIH is distinctive once recognised:

• Daily headache, often retro-orbital or global, worst on waking, worse when lying flat, and worsened by Valsalva manoeuvres (coughing, sneezing, bending over). This is not a typical migraine pattern.
• Transient visual obscurations (TVO): brief seconds-long greying or dimming of vision, typically with postural change or Valsalva — a pathognomonic-leaning feature of papilloedema. Ask about this specifically.
• Pulsatile tinnitus: a rhythmic whooshing or pulsing in one or both ears in time with the heartbeat, present in approximately 60% of patients with IIH. Many patients do not volunteer this without direct questioning.
• Diplopia (horizontal, from a sixth cranial nerve palsy): present in 10–20% — the sixth nerve has the longest intracranial course and is particularly vulnerable to raised pressure.
• Visual field defects: enlarged blind spot, peripheral constriction, arcuate scotoma — up to 75% have visual field abnormalities at diagnosis, often without noticing them.
• Decreased visual acuity: a late, ominous feature indicating optic nerve damage has already occurred.

Photophobia, neck stiffness, back pain, and cognitive complaints are common accompaniments.

Examination — what to do in general practice

Fundoscopy is the key examination. Papilloedema must be identified or excluded. Direct ophthalmoscopy allows examination of the optic disc: look for blurred margins, disc elevation, loss of the physiological cup, and surrounding haemorrhages. If papilloedema cannot be confidently assessed with available equipment, refer for same-day ophthalmology review.

A complete neurological examination is also required. The examination should be normal except for a possible sixth cranial nerve palsy. Any other neurological finding raises the probability of an alternative diagnosis (mass lesion, demyelination, vasculitis).

Check visual acuity (Snellen), pupillary reflexes (a relative afferent pupillary defect is an ominous sign), eye movements, and perform a basic visual field assessment by confrontation.

Record BMI, blood pressure, and drug history.

Mandatory investigations

1. MRI brain plus MR venogram (MRV) — non-negotiable in every patient with suspected IIH. The MRV is specifically required to exclude cerebral venous sinus thrombosis (CVST), which produces identical clinical features but requires anticoagulation, not acetazolamide. Treating CVST with acetazolamide alone is potentially fatal. Specify “MRI brain plus MR venogram for suspected IIH” on the referral to ensure the correct sequences are acquired. MBS 63007 is rebatable on a GP referral for papilloedema or suspected raised intracranial pressure.

MRI findings in IIH include: empty sella (CSF herniation into the pituitary fossa), posterior globe flattening, perioptic subarachnoid space distension, optic nerve tortuosity, and transverse sinus stenosis (present in more than 90% — both cause and consequence, resolving with treatment).

2. Lumbar puncture — opening pressure measurement in the lateral decubitus position with legs extended and the patient fully relaxed. Sitting position will give a falsely elevated reading. Adult threshold is >25 cm H₂O (>28 cm H₂O in obesity or children). CSF studies: protein, glucose, cell count, cytology, oligoclonal bands — all should be normal. Perform lumbar puncture after MRI, not before — mass lesions must be excluded first.

3. Neuro-ophthalmology — baseline formal Humphrey visual field (24-2 or 30-2), OCT retinal nerve fibre layer (OCT-RNFL), and Frisén grading of papilloedema. This is the objective monitoring tool for disease progression and treatment response. MBS 11221 (visual field perimetry) and MBS 11226 (OCT-RNFL).

The modified Dandy criteria (Friedman 2013)

Diagnosis of IIH requires all of the following per Friedman Neurology 2013:

1. Symptoms or signs of raised intracranial pressure.
2. Papilloedema (or, in atypical cases without papilloedema, defined neuroimaging and LP criteria).
3. Normal neurological examination except for a possible sixth nerve palsy.
4. Normal MRI (no mass, no hydrocephalus) with normal MR venogram.
5. Normal CSF composition.
6. LP opening pressure >25 cm H₂O (lateral decubitus, legs extended, relaxed).
7. No other identifiable cause.

B. Evidence appraisal — what the trials show

Acetazolamide — the IIHTT trial

The Idiopathic Intracranial Hypertension Treatment Trial (IIHTT — Wall JAMA 2014) randomised 165 patients with mild visual loss to acetazolamide plus a low-sodium weight-loss diet versus diet alone. Acetazolamide produced significant improvement in visual field (approximately 1.0 dB mean deviation), greater reduction in LP opening pressure, and greater improvement in papilloedema at six months. Most patients tolerated 1–2 g per day; the trial used up to 4 g per day.

Start at 250 mg twice daily and titrate by 250–500 mg every one to two weeks to target 1–2 g per day in two to four divided doses. Common side effects include paraesthesia (approximately 50%), dysgeusia with loss of taste for carbonated drinks (approximately 50%), fatigue, nausea, and metabolic acidosis. Monitor potassium and bicarbonate at two, six, and twelve weeks, then six-monthly. Kidney stone risk is approximately 1–2% per year.

Per AMH, acetazolamide is PBS-listed for glaucoma — not specifically for IIH in Australia. In practice, the glaucoma listing is used (raised ICP causing papilloedema shares the mechanism of elevated ocular pressure damage) and is generally accepted. Private script cost is approximately $15–30 per month.

Topiramate is a useful alternative or adjunct, particularly in patients with comorbid migraine: 25 mg increasing to 100–200 mg per day. Furosemide and spironolactone are adjuncts rather than primary agents.

Weight loss and bariatric surgery — the IIH:WT trial

The IIH:WT bariatric surgery trial (Mollan JAMA Neurology 2021) compared bariatric surgery with a community weight-management programme in patients with IIH and BMI ≥35. Bariatric surgery was significantly superior at reducing intracranial pressure at both twelve and twenty-four months, with durable results. This positions bariatric surgery as a first-line or co-first-line treatment option in BMI ≥35 with persistent IIH despite medical therapy, not merely a last resort.

Even without surgery, a 5–10% reduction in BMI within three to six months puts most patients into clinical remission. Sustained weight maintenance is the long-term goal; IIH recurs with weight regain.

GLP-1 receptor agonists — emerging evidence

The IIH:DT trial (Mollan Brain 2023) showed that exenatide reduced intracranial pressure independently of weight loss. Semaglutide and tirzepatide — which produce substantially greater weight loss than earlier agents — are being used in obese IIH at specialist centres. Neither is currently PBS-listed for obesity in Australia, making the private cost approximately $130–600 per month depending on the agent. Specialist initiation is appropriate.

C. Australian operations

Referral pathway

Any patient with suspected IIH — daily pressure headache, papilloedema on fundoscopy, transient visual obscurations, or unexplained pulsatile tinnitus in a woman with raised BMI — should be referred urgently to neurology or neuro-ophthalmology (within one week) for MRI + MRV and LP with opening pressure. Fulminant IIH (rapid vision loss within four weeks) is a same-day neurosurgical emergency.

In Australia, co-management between neurology and neuro-ophthalmology is standard for all IIH patients. The Royal Victorian Eye and Ear Hospital and equivalent tertiary eye and neurology units at other metropolitan hospitals have IIH multidisciplinary pathways.

What to include in the referral

Full headache and visual symptom timeline; BMI and recent weight trajectory; drug list specifically noting tetracyclines, retinoids, hormonal contraception, and corticosteroids; MRI report if already arranged; any previous visual field results; comorbidities (PCOS, obstructive sleep apnoea, anaemia).

MBS pathways

GP attendance: MBS 23/36/44. MRI brain: MBS 63007. Ophthalmology: MBS 104/105. Neurology: MBS 110/116. Lumbar puncture: MBS 39000. Visual field: MBS 11221. OCT-RNFL: MBS 11226. Bariatric surgery: MBS 31569 (sleeve gastrectomy) for BMI ≥35 with obesity-related comorbidity.

GPCCMP (MBS 965/967) is appropriate for chronic IIH with allied health: dietitian (weight loss, low-sodium diet as used in IIHTT), exercise physiologist (graduated activity, falls precautions with visual impairment), psychologist (chronic illness adjustment, body image, disordered eating screen).

Mental Health Care Plan (MBS 2715/2717) — anxiety, depression, and disordered eating are common comorbidities; threshold should be low.

Driving: visual field defects and diplopia affect driving fitness. Austroads Assessing Fitness to Drive standards require review when visual field loss is present; a conditional licence may be appropriate with regular ophthalmological review.

D. Special populations

Drug-induced secondary intracranial hypertension: tetracyclines (minocycline, doxycycline, lymecycline) and retinoids (isotretinoin) are the most common drug causes in general practice. Presentations are clinically identical to IIH. Stop the offending drug — this alone resolves most cases within weeks. Review the drug list at every visit; new prescriptions for acne or rosacea treatment should prompt a papilloedema screen if the patient has ongoing headaches.

Pregnancy and IIH: IIH does not cause pregnancy complications, but pregnancy can unmask or worsen established IIH. Acetazolamide should be avoided in the first trimester (category B3); the risk-benefit balance in the second and third trimesters requires specialist co-management. Serial visual field monitoring throughout pregnancy is essential. Vaginal delivery is generally safe unless severe papilloedema makes Valsalva dangerous — discuss with the obstetric team.

Men with IIH: male IIH is less common and may follow a more aggressive course. Investigate for secondary causes of raised ICP, including sleep apnoea, hypogonadism, and any drug triggers, before accepting the idiopathic label.

Children: pre-pubertal children with IIH often have an identifiable cause (anaemia, growth hormone therapy, vitamin A excess). The opening pressure diagnostic threshold is higher (>28 cm H₂O). Management follows similar principles with age-appropriate acetazolamide dosing and specialist paediatric neurology/ophthalmology co-management.

When to escalate

Refer urgently (same day, to emergency) for:

• New diplopia with papilloedema and no prior diagnosis — potential CVST
• Rapid vision deterioration (fulminant IIH) — neurosurgical shunting or optic nerve sheath fenestration urgently required
• Severe headache, worst-ever, with papilloedema — subarachnoid haemorrhage must be excluded

Refer urgently (within one week) to neurology or neuro-ophthalmology for:

• All first presentations with suspected IIH
• Any increase in visual field loss or OCT-RNFL thickness on monitoring

Refer semi-urgently (within two weeks) for:

• Visual field deterioration or new symptoms in established, stable IIH
• Failed response to acetazolamide

What this article is and is not

This is general health information drawn from the Therapeutic Guidelines (eTG), Australian Medicines Handbook (AMH), NPS MedicineWise, the Royal Victorian Eye and Ear Hospital IIH guideline, and key clinical trials (IIHTT, IIH:WT, IIH:DT). It does not constitute personal medical advice. IIH requires specialist co-management; decisions about treatment, monitoring, and surgery must be made with your treating neurologist, neuro-ophthalmologist, and GP.

For Australian patient information: Brain Foundation Australia, HealthDirect — IIH, Better Health Channel.

For mental health crisis: Lifeline 13 11 14.

---

Sources cited

1. Therapeutic Guidelines (eTG) — Neurology
2. Australian Medicines Handbook
3. NPS MedicineWise
4. Royal Victorian Eye and Ear Hospital — IIH guideline
5. Brain Foundation Australia
6. Friedman DI et al. Modified Dandy criteria. Neurology 2013
7. Mollan SP et al. UK IIH consensus guidelines. J Neurol Neurosurg Psychiatry 2018
8. Wall M et al. IIHTT. JAMA 2014
9. Mollan SP et al. IIH:WT. JAMA Neurol 2021
10. Mollan SP et al. IIH:DT. Brain 2023
11. Austroads — Assessing Fitness to Drive
12. HealthDirect
13. Better Health Channel